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Objective: This study was conducted to investigate the efﬁcacy and safety of ureteral dilation and
placement of a long-term ureteral stent for patients with various types of ureteral obstructions.
Methods: We retrospectively reviewed the records of 39 patients presenting with ureteral obstruction
secondary to malignant strictures (n ¼ 9) or nonmalignant strictures (n ¼ 30). The mean age of these
patients was 55.8 ± 16.1 years (range, 13e87 years). All patients underwent retrograde ureteral balloon
dilation and placement of one to three ureteral stents. Stent patency rate and complications including
febrile urinary tract infection, stent encrustation, and stent fragmentation were recorded.
Results: A total of 117 ureteral stents were implanted during the 83 procedures. Three stents were placed
in seven patients and two stents in 20 patients. The patency rate was 95.2% with a mean 75-day follow-
up. There was no encrustation in 104 stents and Grade 1 in 13 stents. The patency rate was similar
between the patients with malignant strictures and those with nonmalignant strictures (100% vs. 94.7%,
p ¼ 0.57). However, three episodes of febrile urinary tract infection were noted only in patients with
malignant strictures. The improvement of hydronephrosis and complications were also comparable
between those patients with ureteral stents indwelling for >90 days and those for <90 days. No stent
fragmentation was found in any of the patients.
Conclusion: We demonstrated that ureteral dilation and placement of a single or multiple ureteral stents
was effective and safe for patients with ureteral obstruction.
Copyright © 2015, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
Most urologists have used double-J ureteral stents to treat
ureteral obstruction from various causes for at least 3 decades.1,2
With improvements in modern endourological techniques and
stent biomaterials, most obstructed ureters can be successfully
stented. However, the long-term failure rate of stents has been
high, especially in cases of malignant ureteral compression.1
Segmental metal mesh stents and Resonance metallic stents
seemed promising at the beginning, but the long-term results were
not outstanding.3e5 Although the exact cause of stent failure is not
completely understood, stent lumen compressed by external tu-
mors or occluded by mucus, debris, and stone may be the causes.5
Reviewing previous studies, it was noted that most authors
managed ureteral obstructions by placing a stent for the ureteralEn Chu Kong Hospital, 399,
, Taiwan.
ng).
ciation. Published by Elsevier Taiwstricture without dilation. In addition, some urologists advocated
placing multiple ureteral stents to provide better drainage for pa-
tients who failed with a single stent.1,6 In 2001, Rotariu et al7 re-
ported a simultaneous placement of two ipsilateral ureteral stents
after ureteral dilation. However, this study was small, and only
enrolled seven patients with malignant strictures. Thus, we applied
this concept to a large-scale study to present our early experiences
of performing ureteral dilation ﬁrst, followed by placing additional
stents as needed to treat the ureteral obstruction.
2. Materials and methods
The Institutional Review Board and Ethics Committee of En Chu
Kong Hospital, Taipei, Taiwan approved this study (Identiﬁer ECK-
IRB1021006) and waived the informed consent requirement. Data
were retrospectively obtained from the medical records of 39 pa-
tients who presented with unilateral and/or bilateral ureteral
obstruction and received long-term-type double-J ureteral stent
(Bioteq, Taipei, Taiwan) insertions from January 2009 to December
2013. Of these patients, 21weremen and 18werewomen. Themeanan LLC. Open access under CC BY-NC-ND license.
Fig. 2. Fluoroscopy shows ureteral dilation using a balloon dilator. One indentation
(arrow) was a previous stricture site.
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underlying diseases causing the ureteral obstructionswere stricture
due to long-term impacted ureteral stones (n ¼ 17, 43.6%), benign
intrinsic strictures (n ¼ 10, 25.6%), malignant tumors (n ¼ 9, 23.1%),
and iatrogenic ureteral injuries (n ¼ 3, 7.7%). The upper ureteral
stricture was noted in 25 (64.1%) patients, middle ureteral stricture
in 11 (28.2%) patients, and lower ureteral stricture in three (7.7%)
patients. The ureteral obstructions were detected using ultraso-
nography, intravenous urography, and/or computer tomography
before and after stenting. Stent failure was deﬁned as insufﬁcient
drainage, followed by redilation of the pelvocaliceal system based
on comparative image assessment during the follow-up. In cases of
reobstruction, percutaneous nephrostomy drainage was suggested
to relieve the obstruction and improve renal function. Complica-
tions including febrile urinary tract infection (UTI), stent encrusta-
tion, and fragmentation of the indwelling catheter were recorded
for analysis. The score of stent encrustation was quantiﬁed by the
following visual analog score: 0 (no visible stent bioﬁlm), 1 (visible
stent bioﬁlm), 2 (bladder coil encrustation), 3 (<50% of the entire
stent encrusted), and 4 (>50% of the stent encrusted).8
The ureteral stents were inserted using retrograde techniques.
Patients were placed in a lithotomy position with light intravenous
anesthesia or general anesthesia. All procedures were performed
under ﬂuoroscopic guidance. First, a 21F cystoscopy (Richard Wolf
GmbH, Knittlingen, Germany) was performed, and a 0.035-inch hy-
drophilic ﬂoppy Nitinol core guide wire, HiWire (Cook Medical,
Bloomington, IN, USA), was inserted into the ureteral oriﬁce. Next,
using a 6.5F semirigid ureteroscope (Richard Wolf), a diagnostic
ureteroscopy was performed to examine the constricted portion of
the ureter. When the stricture location was identiﬁed, 10e20 mL
contrast medium, Telebrix (Guerbet, Villeprinte, France) in a 1:1
mixturewith normal salinewas injected through the ureteroscope to
conﬁrm the length and severity of the ureteral stricture (Fig.1). Then,
a secondary ﬂoppy guide wire was inserted into the ureter. After
removing the ureteroscope, a 5.8F balloon dilation catheter, UroMax
Ultra (Boston Scientiﬁc,Natick,MA,USA),was inserted into the ureter
through the guidewire. About 3mL contrastmediumwas injected to
inﬂate the balloon, and the stricture site was dilated for at least 10
minutes (Fig. 2). Another diagnostic ureteroscopywas examined, and
in the case of inadequate lumen at the stricture site, ureteral dilation
was repeated.We consciously tried to place two or three 6F double-JFig. 1. Fluoroscopy shows middle ureteral stenosis (arrow) with proximal hydroureter.ureteral stents (Figs. 3 and 4) at the end of procedures depending on
our clinical judgment. Because previous studies and our previous
experiences have found that a single ureteral stent might not be
sufﬁcient to relieve obstruction for patientswithureteral obstruction,
it became our routine procedure to place multiple stents if possible
after 2009. The reason for placing more stents was to increase the
theoretical space between the parallel stents (Fig. 5). In cases where
we encountered difﬁculty inserting the second ureteral stent, only
one ureteral stent was placed in the ureter. The position of the ure-
teral stents was checked ﬁnally by ﬂuoroscopy.
Mean and standard deviations were used for parametric,
continuous variables. Categorical data were expressed as numbers
and percentages. Mean values of continuous variables were
compared using the ManneWhitney U-test, whereas categorical
variables were compared using the Fisher exact test. A p value
<0.05 was considered statistically signiﬁcant.Fig. 3. Plain kidney, ureter, and bladder radiograph shows two double-J stents placed
in the left ureter.
Table 1
Comparison of efﬁcacy and safety in patients with malignant and nonmalignant
strictures.
Malignant
stricture
Nonmalignant
stricture
p
Patient number 9 30
Duration of placement (d) 81.2 ± 15.0 73.4 ± 14.2 0.06
Patency rate (procedure) 21/21 (100) 58/62 (93.5) 0.57
Febrile UTI (procedure) 3/21 (14.3) 0/62 (0) 0.01
Grade 1 stent encrustation 5/24 (20.8) 8/93 (8.6) 0.14
Fragmentation of ureteral stent 0/24 (0) 0/93 (0) 1
Data are presented as n/N (%) or mean ±SD.
UTI ¼ urinary tract infection.
Table 2
Comparison of efﬁcacy and safety in patients with indwelling ureteral stents for
more than and less than 90 days.
90 d <90 d p
Duration of placement (d) 98.0 ± 11.7 67.7 ± 9.5 <0.01
Patency rate (procedure) 21/21 (100) 58/62 (93.5) 0.57
Febrile UTI (procedure) 0/21 (0) 3/62 (4.8) >0.99
Grade 1 stent encrustation 3/24 (12.5) 10/93 (10.8) 0.73
Data are presented as n/N (%) or mean ± SD.
UTI ¼ urinary tract infection.Fig. 4. Plain kidney, ureter, and bladder radiograph shows three double-J stents placed
in the left ureter.
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A total of 117 double-J ureteral stents were placed during the
83 procedures in the 39 patients. We changed the ureteral stents
in nine patients with malignant strictures regularly until they
passed away. Three ureteral stents were inserted in seven patients
and two stents in 20 patients. The mean length of the ureteral
stricture was 1.2 ± 0.5 cm (range 0.4e2.5 cm). The mean place-
ment duration was 75.3 ± 15.6 days (range 55e140 days).
Improvement of hydronephrosis was found in all patients with
three stents and in 19 (95%) of the patients with two stents.
Persistent hydronephrosis was only noted after three procedures
(4.8%) in two patients with a single stent. Among the 30 patients
with nonmalignant strictures, one (3.3%) patient underwent open
repair of the ureteral stricture because of persistent hydro-
nephrosis after two times of endoscopic management. Three pa-
tients (7.7%) had postoperative febrile UTIs, and all patients
recovered after adequate treatment with broad-spectrum antibi-
otics. Grade 0 encrustation was noted in 108 ureteral stents, Grade
1 was noted in 13 (11.1%) ureteral stents, and no encrustation was
noted at Grades 2e4 was noted. No fragmentations of the
indwelling stents were identiﬁed.
Table 1 compares the patency rate and safety of stents in patients
with malignant and nonmalignant strictures. In nine patients with
malignant strictures, 21 procedures with 24 ureteral stents were
performed. In the other 30 patientswith nonmalignant strictures, 62
procedures with 93 stents were performed. Patients with malignant
strictureshadaborderline signiﬁcantly longerdurationof indwellingFig. 5. (A) Extrinsic ureteral compression decreasing the theoretical space around the stents
More space between the three parallel stents.ureteral stent (81.2 ± 15.0 vs. 73.4 ± 14.2, p ¼ 0.06) and signiﬁcantly
more episodes of febrile UTIs (14.3% vs. 0%, p¼ 0.01) than thosewith
nonmalignant strictures. However, the stent patent rate and stent
encrustation were comparable between the two groups.
We further analyzed the data for 21 procedures in 10 patients
where the double-J ureteral stents remained for more than 90 days.
Table 2 shows the comparisonof efﬁcacyand safety betweenpatients
with indwelling ureteral stents for >90 days and <90 days. The
improvement rate ofhydronephrosiswas comparable inbothgroups.
In addition, the complication rate including febrile UTIs and stent
encrustation was not signiﬁcantly different between the groups.4. Discussion
In this retrospective study, we demonstrated the efﬁcacy and
safety of mid- to long-term indwelling ureteral stents in patients
with various etiologies of ureteral obstruction. A highly successful
patent rate (95.2%) was noted during the mean 75-day follow-up.
Excellent results were also noted in some patients with multiple
stents. Only very mild stent encrustation and a few febrile UTIs
occurred.
In our study, the patency rate was comparable between the
malignant strictures and nonmalignant strictures. This result was
similar or superior to the results of other studies using conventional
stents or even metallic stents.4,6,9,10 This good outcome may be
attributable to our additional step of ureteral dilation using a high-
pressure balloon dilator instead of simply placing a stent. We also
routinely used ﬂuoroscopy to conﬁrm the stricture site. These. (B) Patent space between the parallel stents despite extrinsic ureteral compression. (C)
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resist the progressive extrinsic compression of metastatic cancer.
However, a higher febrile UTI rate was noted in our cancer patients.
These patients were concomitantly treated by chemotherapy and/
or radiotherapy. Poor nutrition and lowered immunity may in-
crease the higher infection rate in these compromised patients.
Thus, prophylactic strong broad-spectrum antibiotics were sug-
gested prior to the ureteral stent placement.
We also noted ongoing long-term efﬁcacy and safety in patients
with placement durations of >90 days. No stent encrustation or UTI
was noted in one case with the highest indwelling period of 140
days. This ﬁnding is important because our experience has indi-
cated that inserting ureteral stents for only a few weeks is insufﬁ-
cient for some patients with refractory benign ureteral stricture.
Long-term indwelling ureteral stents are necessary to resolve the
stricture completely. One in vitro encrustation study showed that
polyurethane stents, our stent material, had a low encrustation
rate.11,12 Thus, our preliminary result suggests that implanting
ureteral stents for more than 3 months can be safe and effective.
Since Borin et al13 reported the ﬁrst case of Resonance stents to
relieve malignant ureteral obstruction in 2006, some studies have
reported that themetallic stent, with its unique alloy design, has the
beneﬁt of offering longer resistance against extrinsic compression. In
most studies, the median duration ranged from 3.5 months to 11
months, depending on the patient's characteristics and the etiology
of the obstruction.3,4,13,14 Recently, Chow et al4 reported the largest
series (involving 117 stents), indicating that themedian durationwas
5.8 months and suggesting that the preoperative serum creatinine
level and presence of lower gastrointestinal tract cancer were
signiﬁcantly associatedwith stent failure. The 3-month and 6-month
patent rateswere 65% and44.4%, respectively. Because of the varying
etiologies, different follow-up period, and stent numbers among
these studies, we cannot concludewhich method is better, although
our patent rate was high at 95% with 75 days of follow-up.
The use of two ipsilateral ureteral stents for relief of ureteral
obstruction was ﬁrst proposed by Liu and Hrebinko1 in 1998. They
placed two 4.7 F parallel stents in four patients who had persistent
azotemia and hydronephrosis after a single 6F double-J stent. They
declared that the main advantages were the increased stiffness of
two stents to reduce kinking and the increased potential space
between the stents to preserve ﬂow passage. In 2002, Fromer et al6
used two double pigtail stents for malignant ureteral obstruction
and found that the simultaneous placement of two ipsilateral stents
provided more resistance against lumen compression. As for the
safety concerns regarding multiple stents, to our knowledge, there
is no in vivo or ex vivo report of single or multiple ureteral stents
inducing ureteral mucosal ischemia. In our series, we further
increased up to three stents in seven cases. All seven patients had
hydronephrosis improvement, and the mean placement duration
was 69.9 days. Interestingly, they had few irritative symptoms and
noted that the stent-related ﬂank pain was tolerable.
It is not difﬁcult to resolve the technique problem, wherein the
ﬁrst ureteral stent would be pushed upward during the insertion of
the second stent. First, we would try to change the insertion angle
to avoid push-back. Second, in case of invisible bladder coil, we
would not perform ureteroscopy to grasp the stent downward us-
ing ureteral forceps because many stents would slip downward
spontaneously during the follow-up period. Third, the invisible
ureteral stent might be removed simultaneously during the pro-
cedure of removing a ureteral stent. Finally, if all of these pro-
cedures failed, we could perform ureteroscopy and use ureteral
forceps to remove the ureteral stent.
The study has several limitations. First, this is a retrospective
study. Second, the number of indwelling ureteral stents was not
ﬁxed and depended on the clinical conditions. A prospectiverandomized trial is still needed to decide whether more stents can
bring more beneﬁts to these patients. Third, the timing of removing
or changing the ureteral stent was based on clinical judgment, not
on a ﬁxed interval. We did ﬁnd that the time interval of stent
changewas every 3e6months in several studies. However, because
the efﬁcacy and safety of ureteral stents (Bioteq) had not been
completely understood in our preliminary study, we chose a
slightly shorter duration than that used in other studies for safety
considerations. In addition, in case of persistent hydronephrosis or
febrile UTI, we changed the ureteral stents early. Thus, the mean
period of stent change was shortened (mean 75 days). Finally,
because some urologists have advocated the efﬁcacy and safety of
metallic stents in single-center observations, future prospective,
multicenter, randomized trials to compare the cost and beneﬁt
between metallic and polyurethane stents are needed.
5. Conclusion
Our study demonstrated that benign or malignant ureteral ob-
structions could be treated effectively and safely with single or
multiple ureteral stents. Long-term use, i.e., >3months, is sufﬁcient
for some selected patients and appears feasible. Careful ureteral
dilation prior to stenting is suggested for better results.
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